Riluzole use in presence of contraindications in adults affected by amyotrophic lateral sclerosis and its off-label use in other motor neuron diseases: Findings from an Italian multicentre study (the CAESAR project)

Background: This analysis describes the use of riluzole in amyotrophic lateral sclerosis (ALS) individuals with contraindications and off-label for subjects other motor neuron diseases (o-MND) Italian regions Latium, Tuscany Umbria. Methods: A cohort adults ALS prescribed during years 2016–2019 was enrolled from administrative healthcare databases, excluding o-MND preceding 5 years. Being affected by more than years, presence tracheostomy, renal or hepatic failure were considered as to riluzole. whom retrieved up 4 analysing over time differences related sex. Results: Among 206 336 60 Umbria, less 1% diagnosed Less 2% tracheotomised failure. Renal documented 1.9%, 2.7%, 5.0% The comprised 264 222 Tuscany, 66 Non-negligible observed: 8.5%, 33.0%, 4.2% females, 19.9%, 26.5% 2.4% males Discussion: Riluzole is rare, slightly higher numbers Off-label found be non-negligible, variations between sexes.